Use of recombinant factor VIIa prior to lumbar puncture in pediatric patients with acute leukemia.
The persistence of abnormal coagulation test results after standard treatment with fresh frozen plasma (FFP) poses significant problems in children with acute leukemia requiring a diagnostic lumbar puncture and intrathecal chemotherapy. We report the prophylactic use of a single dose of 90 microg/kg recombinant activated factor VII (rFVIIa) in three children and the rapid correction of abnormal coagulation test results previously not corrected by FFP. Administration of rFVIIa was useful in avoiding a delay of diagnostic lumbar punctures and intrathecal chemotherapy. Hemorrhagic complications and adverse effects of rFVIIa were not observed. Prospective evaluation of this indication and dose appears warranted. (c) 2005 Wiley-Liss, Inc.
Das
Prabodh
P
The Hospital for Sick Children, Division of Hematology/Oncology, Department of Pediatrics, University of Toronto, Toronto, Ontario M5G1X8, Canada.
Carcao
Manuel
M
Hitzler
Johann
J
D000293:Adolescent; D001778:Blood Coagulation Disorders / Q000209:etiology / Q000628:therapy*; D002648:Child; D015942:Factor VIIa / Q000627:therapeutic use*; D006470:Hemorrhage / Q000517:prevention & control*; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000150:complications*; D008297:Male; D011292:Premedication; D011994:Recombinant Proteins / Q000627:therapeutic use; D013129:Spinal Puncture / Q000009:adverse effects*
D011994:Recombinant Proteins; D015942:Factor VIIa